GlaxoSmithKline CFO Interviewed on Q1 2013 Financial Results

LONDON, April 24, 2013 /PRNewswire/ --

GlaxoSmithKline reported a 2% decline in Group revenues in line with expectations and a dividend increase of 6% as part of its 2013 Q1 results. The pharmaceutical giant also officially announced the divestment of Lucozade and Ribena as well as the creation of a 'Global Established Products' group within its portfolio that would get a different strategic focus from the more innovative products.

In a video interview, Chief Financial Officer Simon Dingemans said he felt "very comfortable" about the trends the group was seeing from its performance with strong results from Japan and the US offsetting the tougher European environment.

He emphasized his confidence that the Group was on track to deliver the guidance of 3 to 4% earnings growth in constant currency terms, on sales growth of around 1%. He also highlighted the "significant, continued progress" GSK was making in the pipeline with six new products that had been "called out in front of regulators on both sides of the Atlantic".

The video interview and transcript are available to watch now for free at http://video.merchantcantos.com.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-207-936-1352.

SOURCE GlaxoSmithKline

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.